Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1978 Mar-Apr;73(2):133-46.
doi: 10.1007/BF01906749.

On the mode of action of antianginal drugs

On the mode of action of antianginal drugs

L Szekeres. Basic Res Cardiol. 1978 Mar-Apr.

Abstract

The antianginal action of coronary dilating drugs seems to be related at least partly to their effect of improving the blood supply of the ischemic myocardium. No correlation was found between coronary dilating action of these drugs in the normal myocardium and in the ischemic area, however. It has been shown that coronary dilator drugs are able to produce a further dilatation of the vascular bed which is already in maximum hypoxic dilatation. The antianginal effect of adrenergic beta receptor blockade cannot be explained solely by its negative chronotropic and inotropic action. It involves a favourable redistribution of the coronary flow which is increased in the ischemic area. In addition, there is evidence for a direct cardiac metabolic effect of beta blockade which reduces the myocardial oxygen requirement and moderates the ischemic diminution of the myocardial lactate uptake independently of its action on the autonomic nervous control and other extracardiac factors as well as on contractility, heart rate and myocardial blood supply.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Am J Med. 1951 Sep;11(3):331-57 - PubMed
    1. Circulation. 1972 Dec;46(6):1079-97 - PubMed
    1. Acta Med Acad Sci Hung. 1975;32(3-4):349-56 - PubMed
    1. J Pharmacol Exp Ther. 1976 Jan;196(1):15-28 - PubMed
    1. Adv Pharmacol. 1964;3:1-82 - PubMed

MeSH terms